<DOC>
	<DOCNO>NCT00140374</DOCNO>
	<brief_summary>The objective study evaluate safety efficacy prim vaccination , subsequent boosting vaccination GVAX® Vaccine Prostate Cancer . Clinical observation laboratory measurement monitor evaluate safety toxicity . Additionally , antitumor effect GVAX® Vaccine Prostate Cancer serum PSA level , evaluate antitumor response quantitated .</brief_summary>
	<brief_title>Vaccination Priming Vaccine Boosting Trial Allogeneic Human GM-CSF Gene Transduced Irradiated Prostate Cancer Cell Vaccines ( GVAX® Vaccine Prostate Cancer )</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Diagnosis adenocarcinoma prostate cancer recur surgery PSA No evidence measurable metastatic disease An ECOG performance status 0 1 Transitional cell , small cell squamous cell prostate carcinomas Any previous radiation therapy , prior antiandrogens prior investigational therapy Previous hormonal therapy type prostate cancer Previous biological therapy cancer</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2005</verification_date>
	<keyword>Prostate</keyword>
	<keyword>Cancer</keyword>
	<keyword>Vaccine</keyword>
	<keyword>GVAX</keyword>
	<keyword>Allogeneic cell</keyword>
</DOC>